In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...